IRVINE, CA, Biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, today announced that its current investor group was joined by Partners & Partners to fund the second $10 million tranche of a total possible financing of $30 million.
Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, today announced that its current investor group was joined by Partners & Partners to fund the second $10 million tranche of a total possible financing of $30 million. The financing was triggered by the company's successful achievement of revenue milestones ahead of schedule and the final investment of $10 million will again be based on continued commercial metrics.
The proceeds will be used to fund the nationwide commercial launch of MIRISK VP, Aviir's proprietary cardiac risk assessment technology, and additional laboratory testing services provided through Aviir Diagnostic Laboratories, based in Irvine, California. Merck Global Health Innovation Fund led the round. Merck was joined by Partners & Partners. Current investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners also participated.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event.
Aviir's proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years. Aviir's CLIA certified laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders - including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com
for more information.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about